Compare ARGX & NKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARGX | NKE |
|---|---|---|
| Founded | 2008 | 1964 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Shoe Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4B | 77.5B |
| IPO Year | 2017 | 1996 |
| Metric | ARGX | NKE |
|---|---|---|
| Price | $987.84 | $39.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 26 |
| Target Price | ★ $1,008.56 | $63.44 |
| AVG Volume (30 Days) | 276.8K | ★ 19.2M |
| Earning Date | 05-07-2026 | 03-31-2026 |
| Dividend Yield | N/A | ★ 3.69% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.10 |
| Revenue | N/A | ★ $46,398,000,000.00 |
| Revenue This Year | $44.39 | $0.91 |
| Revenue Next Year | $20.84 | $0.56 |
| P/E Ratio | $33.69 | ★ $19.41 |
| Revenue Growth | N/A | ★ 0.19 |
| 52 Week Low | $650.01 | $40.00 |
| 52 Week High | $953.58 | $80.17 |
| Indicator | ARGX | NKE |
|---|---|---|
| Relative Strength Index (RSI) | 68.84 | 35.30 |
| Support Level | $829.21 | N/A |
| Resistance Level | N/A | $46.98 |
| Average True Range (ATR) | 25.25 | 0.99 |
| MACD | 7.47 | -0.22 |
| Stochastic Oscillator | 93.94 | 0.00 |
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Nike is the largest athletic footwear and apparel brand in the world. Footwear generates about two-thirds of its sales. Key performance footwear categories include basketball, running, and football (soccer). Its brands include Nike, Jordan (premium athletic footwear and clothing), NikeSkims (women's athleisure), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores (including about 5,500 in China), and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.